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Abstract
Introduction: Although alcohol consumption is a common lifestyle behavior with previous studies reporting
positive effects of alcohol on chronic pain and rheumatoid arthritis, no studies to this date have examined alcohol
consumption in patients with fibromyalgia. We examined the association between alcohol consumption and
symptom severity and quality of life (QOL) in patients with fibromyalgia.
Methods: Data on self-reported alcohol consumption from 946 patients were analyzed. Subjects were grouped by
level of alcohol consumption (number of drinks/week): none, low (≤3), moderate (>3 to 7), and heavy (>7).
Univariate analyses were used to find potential confounders, and analysis of covariance was used to adjust for
these confounders. Tukey HSD pairwise comparisons were used to determine differences between alcohol groups.
Results: Five hundred and forty-six subjects (58%) did not consume alcohol. Low, moderate, and heavy levels of
alcohol consumption were reported for 338 (36%), 31 (3%), and 31 patients (3%), respectively. Employment status
(P <0.001), education level (P = 0.009), body mass index (P = 0.002) and opioid use (P = 0.002) differed significantly
among groups with drinkers having higher education, a lower BMI, and a lower frequency of unemployment and
opioid use than nondrinkers. After adjusting for these differences, the measures including the number of tender
points (P = 0.01), FIQ total score (P = 0.01), physical function (P <0.001), work missed (P = 0.005), job ability (P =
0.03), and pain (P = 0.001) differed across groups, as did the SF-36 subscales of physical functioning (P <0.001),
pain index (P = 0.002), general health perception (P = 0.02), social functioning (P = 0.02), and the physical
component summary (P <0.001). Pairwise comparison among the 4 groups showed that the moderate and low
alcohol drinkers had lower severity of fibromyalgia symptoms and better physical QOL than nondrinkers.
Conclusions: Our study demonstrates that low and moderate alcohol consumption was associated with lower
fibromyalgia symptoms and better QOL compared to no alcohol consumption. The reasons for these results are
unclear. Since recent studies have demonstrated that g-Aminobutyric Acid (GABA) levels are low in fibromyalgia,
and alcohol is known to be a GABA-agonist, future studies should examine whether alcohol could have a salutary
effect on pain and other symptoms in fibromyalgia.
Introduction
Fibromyalgia is a chronic condition characterized by
widespread pain, tenderness, and decreased pain thresh-
old to pressure and other stimuli [1,2]. It is often asso-
ciated with fatigue, unrefreshing sleep, and cognitive
symptoms as well as multiple other somatic symptoms
including headache, irritable bowel and bladder symp-
toms, and depression [3]. Although the cause of fibro-
myalgia is unclear, extensive research has helped
understanding of fibromyalgia and indicates that fibro-
myalgia is a central amplification disorder of pain per-
ception resulting from neurochemical imbalances in the
central nervous system [4-6].* Correspondence: oh.terry@mayo.edu1Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester,
MN 55905, USA
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Alcohol consumption has both harmful and beneficial
effects on health. On the one hand, drinking large
amounts of alcohol for years is hazardous [7]. On the
other hand, epidemiologic and clinical evidence suggests
that moderate drinking is associated with a reduced risk
of cardiovascular disease [8] and ischemic stroke [9]. In
US adults, moderate alcohol consumption is considered a
lifestyle behavior that supports cardiovascular health, in
conjunction with a prudent diet, regular physical activity,
a healthy weight, and not smoking [10]. Furthermore,
regular low-to-moderate alcohol consumption has been
associated with better quality of life (QOL), mood, and
subjective health in studies of young and older adults
[11-16] and a protective factor for better health in a gen-
eral population with and without chronic musculoskeletal
pain [17,18].
Studies on alcohol consumption in chronic pain have
shown conflicting results. Whereas a systematic review
showed no positive association or dose response between
alcohol consumption and low back pain [19], individual
studies of men with back pain disability showed that
those who consumed large amounts of alcohol had less
physical disability, despite similar pain [20], and those
who consumed alcohol regularly were less likely to have
associated chronic pain [21]. Epidemiologic studies on
alcohol and rheumatoid arthritis have reported interest-
ing results, namely that moderate alcohol consumption
may decrease the risk of rheumatoid arthritis develop-
ment, severity and progression, possibly by reducing
levels of some inflammatory markers [22-24].
Although alcohol consumption is a common lifestyle
behavior, no studies to date have examined alcohol con-
sumption in the setting of fibromyalgia. The objective of
this study was to evaluate the association between alcohol




This study was approved by the Mayo Clinic Institutional
Review Board, and all patients provided written consent to
participate in the study. This is a cross-sectional study
using data of patients previously described [25]. Partici-
pants were seen in the Fibromyalgia Treatment Program
(FTP) during the study period from May 1, 2001, through
April 30, 2004, and had the confirmed diagnosis of fibro-
myalgia according to the 1990 American College of Rheu-
matology criteria [1]. All patients were older than 18 years,
had history of alcohol consumption in the electronic med-
ical record, and had completed the Fibromyalgia Impact
Questionnaire (FIQ) [26] and the Short Form-36 Health
Survey (SF-36) [27,28] at the time of evaluation in the
FTP. All participants underwent a standardized evaluation,
including a tender-point assessment by a registered nurse.
Demographic and social variables and the number of ten-
der points were abstracted from the medical record.
Alcohol consumption determination and grouping
Alcohol consumption data (self-reported alcohol history,
taken as a part of the social history) were collected from
the electronic medical record. If patients were current
alcohol users, they were asked specifically about the fre-
quency of use per week or month, the number of drinks
consumed per each time, and the type of beverage con-
sumed. One drink was defined as 12 fluid ounces of regu-
lar beer (5% alcohol), 5 fluid ounces of wine (12%
alcohol), or 1.5 fluid ounces of distilled spirits (40% alco-
hol) [29]. We calculated drinks per week by multiplying
the frequency of use per week with the number of drinks
per each time. Subjects were grouped by the level of alco-
hol consumption (number of drinks per week): none, low
(≤3), moderate (>3 to 7), and heavy (>7), consistent with
guidelines from the National Institute on Alcohol Abuse
and Alcoholism, which distinguish between low-risk and
at-risk consumption patterns [29]. We did not differenti-
ate on the basis of beverage type for this study.
Fibromyalgia-related symptoms and QOL assessment
Participants completed the FIQ and the SF-36 at the time
of their evaluation in the FTP. The FIQ was first published
in 1991 and was designed to assess health status specifi-
cally in patients with fibromyalgia [26]. It is a self-adminis-
tered questionnaire that measures multiple domains of
fibromyalgia symptoms and functional impairment, and it
contains 20 questions that assess the following areas: phy-
sical functioning, overall well-being in the previous week,
days of work missed, and symptoms of pain, fatigue,
morning tiredness, stiffness, job difficulty, anxiety, and
depression. Possible scores range from 0 to 100, with a
high score indicating a greater impact of fibromyalgia-
related symptomatology [26]. The FIQ was scored accord-
ing to the directions outlined by Bennett [30].
The SF-36 consists of 36 questions to assess health-
related QOL. It was developed as a potential tool for mon-
itoring patient outcomes in a busy clinical setting [27,28].
It is a self-administered questionnaire that measures eight
health concepts: physical functioning, role limitation due
to physical health, pain index, general health perception,
vitality score, social functioning, role limitations due to
emotional health, and mental health. It also provides phy-
sical composite and mental composite scores. The SF-36
score can range from 0 to 100, with higher scores indicat-
ing better health status [28].
Statistical analysis
Demographic and social characteristics were compared
across alcohol consumption groups using one-way analysis
of variance (ANOVA) for continuous variables and chi
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square (c2) tests for categorical variables. Unadjusted com-
parisons of the numeric rating scale for pain, number of
tender points, and FIQ and SF-36 scores across groups
were performed using one-way ANOVA. Analysis of cov-
ariance (ANCOVA) was used to adjust comparisons for
potential confounders across the four alcohol groups. For
the multivariate ANCOVA models, potential confounders
were selected based on either being clinically important
(age) or showing significance from univariate analyses
(employment status, education level, body mass index
(BMI), and opioid use). Univariate collinearity evaluations
were done to rule out correlated covariates. None of the
covariates were strongly correlated. The Tukey honestly
significant difference (HSD) method was used to perform
pairwise comparisons of least-squares means between
alcohol consumption groups, adjusted for baseline differ-
ences, when the overall effect in the multivariable model
was found to be statistically significant. P values <0.05
were considered statistically significant. Analysis was per-




Among the 988 patients seen during the study period,
42 patients had incomplete data on alcohol consump-
tion and were excluded from further analysis. The final
study subjects consisted of 946 fibromyalgia patients
(893 women) with a mean age of 49 years (SD, 12.7).
Patient characteristics, stratified by level of alcohol con-
sumption, are shown in Table 1. Five hundred and
forty-six subjects (58%) did not consume alcohol. Low,
moderate, and heavy levels of alcohol consumption were
reported for 338 (36%), 31 (3%), and 31 patients (3%),
respectively. Employment status (P <0.001), education
level (P = 0.009), (BMI) (P = 0.002), and opioid use (P =
0.002) differed significantly across the four groups, with
drinkers having higher education, a lower BMI, and a
lower frequency of unemployment and opioid use than
nondrinkers (Table 1).
Comparison of symptoms and QOL among patient
groups
After adjusting for age, employment status, education
level, BMI and opioid use, we found significant group dif-
ferences in the number of tender points (P = 0.01) (Table
2), FIQ total score (P = 0.01), FIQ subscales of physical
function (P <0.001), work missed (P = 0.005), job ability
(P = 0.03), and pain (P = 0.001) (Table 3), and SF-36 sub-
scales of physical functioning (P <0.001), pain index (P =
0.002), general health perception (P = 0.02), social func-
tioning (P = 0.02), and physical component summary
(P <0.001) (Table 4). Pain scores were significant on
unadjusted analysis and became not significant on
adjusted analysis (Table 2). Moderate drinkers had over-
all lower fibromyalgia-related symptoms, and higher
QOL scores than the other groups.
Pairwise comparison among the four groups showed
that the moderate and low alcohol drinkers had better
physical QOL than nondrinkers, with significant differ-
ences for SF-36 physical functioning, pain index, and
physical component summary scores (Table 5). Addi-
tionally, low drinkers had better scores of SF-36 general
health perceptions and social functioning scales than
nondrinkers. For heavy drinkers, the only significant
finding was better scores on the SF-36 physical func-
tioning scale than nondrinkers. Regarding the severity of
fibromyalgia-related symptoms, the moderate drinkers
had significantly lower FIQ pain scores than all other
groups, better FIQ total scores than nondrinkers, better
physical function than nondrinkers, and fewer tender
points than low drinkers. Also, low drinkers had better
scores on FIQ work missed, and on physical function
than nondrinkers.
Discussion
Our cross-sectional study demonstrates that for patients
with fibromyalgia, low and moderate alcohol consump-
tion was associated with lower fibromyalgia symptoms
and better QOL compared to no alcohol consumption.
Drinkers had higher education, a lower BMI and a lower
frequency of unemployment and opioid use than non-
drinkers. Among drinkers, moderate alcohol consump-
tion was associated with lower FIQ pain scores than low
and heavy drinkers, and a lower number of tender points
than low drinkers even after adjusting for confounding
covariates. The reasons for these results are unclear.
To our knowledge, no other reports on alcohol con-
sumption, symptom severity, and QOL in patients with
fibromyalgia have been published to date, which limits
our ability to further validate our findings. However, in
the general population, those who had low to moderate
alcohol consumption had better QOL scores in physical
and mental domains of SF-36 [12,14], especially in the
physical domains [11,16]. Also, in a cross-sectional study
[21] those who consumed alcohol regularly were less
likely to have chronic pain, and regular alcohol consump-
tion has been shown to be protective of better health in a
general population with and without chronic musculos-
keletal pain [17,18], as well as being associated with
lower risk and severity of rheumatoid arthritis [23]. Our
results were generally similar to these studies in terms of
better QOL scores, especially for the physical domains,
for the low and moderate drinkers.
It is notable that we did not observe the same associa-
tion in heavy drinkers. The only significant finding in
heavy drinkers as compared to nondrinkers was better
scores on the SF-36 physical functioning scale. This
Kim et al. Arthritis Research & Therapy 2013, 15:R42
http://arthritis-research.com/content/15/2/R42
Page 3 of 8
finding suggests that there are other unknown factors or
comorbid conditions affecting fibromyalgia symptoms
and QOL. Clinical and epidemiological studies have sug-
gested an association between excessive alcohol con-
sumption and major depressive episodes [31]. Although
our study was not meant to adequately assess depres-
sion, we did not observe significant differences in the
FIQ depression nor SF-36 mental component summary
scores between the groups. Binge drinking (five or more
drinks on one occasion) is reported to be associated with
many health problems, including worse QOL and mental
distress [32,33]. There were five binge drinkers (16%) in
our heavy drinker group, who had overall worse scores in
the FIQ and SF-36 than non-bingeing heavy drinkers:
mean FIQ total 74.5 (SD 17.1) vs 59.8 (14.7), SF-36 physi-
cal component summary 29.8 (7.9) vs 30.1(9.3) and SF-36
Table 1 Patient characteristics (number of patients = 946)









Female, n (%) 517 (94.7) 318 (94.1) 28 (90.3) 30 (96.8) 0.69
Age, y, mean (SD) 49 (13.1) 48 (12.0) 52 (12.3) 52 (14.3) 0.08
Race/ethnicity, n (%) 0.50
White 536 (98.2) 335 (99.1) 31 (100) 30 (96.8)
Nonwhite 10 (1.8) 3 (0.9) 0 (0) 1 (3.2)
Abuse history, n/total (%) 155/537 (28.9) 108/334 (32.3) 9 (29.0) 12 (38.7) 0.53
Current tobacco user, n/total (%) 80/543 (14.7) 45 (13.3) 7 (22.6) 5 (16.1) 0.55
Marital status, n (%) 0.90
Married 421 (77.1) 252 (74.6) 22 (71.0) 23 (74.2)
Unmarried 114 (20.9) 78 (23.1) 8 (25.8) 8 (25.8)
Widowed 11 (2.0) 8 (2.4) 1 (3.2) 0 (0)
Employment status, n (%) <0.001
Employed 255 (46.7) 213 (63.0) 20 (64.5) 14 (45.2)
Homemaker 56 (10.3) 19 (5.6) 2 (6.5) 5 (16.1)
Retired 70 (12.8) 33 (9.8) 5 (16.1) 6 (19.4)
Unemployed 165 (30.2) 73 (21.6) 4 (12.9) 6 (19.4)
Education level, n/total (%) 0.009
<12th grade 24/538 (4.5) 6/334 (1.8) 1 (3.2) 2/30 (6.7)
High school 188/538 (34.9) 89/334 (26.7) 9 (29.0) 7/30 (23.3)
Some college or technical college 171/538 (31.8) 110/334 (32.9) 5 (16.1) 10/30 (33.3)
College, graduate school 155/538 (28.8) 129/334 (38.6) 16 (51.6) 11/30 (36.7)
Body mass index, kg/m2, mean (SD) 30.5 (7.4) 29.2 (7.2) 27.4 (6.0) 27.0 (4.3) 0.002
Opioid use, n/total (%) 155/545 (28.4) 67 (19.8) 2 (6.45) 6 (19.35) 0.002
Benzodiazepine use, n/total (%) 120/545 (22.0) 61 (18.1) 4 (12.9) 9 (29.0) 0.21
Alcoholic drinks consumed per week, mean number (SD) ... 0.5 (0.7) 5.8 (1.2) 14.8 (8.5) ...
aAlcohol consumption levels were defined as follows: none, 0 drinks/wk; low, ≤3 drinks/wk; moderate, >3 to 7 drinks/wk; heavy, >7 drinks/wk. n, number of
patients.
Table 2 Comparison of pain and tender points with alcohol use (number of patients = 946)










Pain score, mean (SD)c
Now 6.2 (1.7) 5.8 (1.9) 5.4 (1.9) 5.5 (1.4) 0.003 0.11
Best 3.9 (1.9) 3.6 (1.8) 2.9 (1.6) 3.2 (1.7) 0.002 0.13
Worst 9.3 (1.6) 9.1 (1.6) 8.5 (1.7) 8.8 (1.8) 0.01 0.21
Tender points, mean number (SD) 16.2 (2.1) 16.3 (2.1) 14.9 (2.7) 15.3 (2.6) 0.001 0.01
aAlcohol consumption levels were defined as follows: none, 0 drinks/wk; low, ≤3 drinks/wk; moderate, >3 to 7 drinks/wk; heavy, >7 drinks/wk. bAfter adjusting for
age, employment status, education level, body mass index and opioid use. cPain score was evaluated using a numeric rating scale (range of possible scores, 1 to 10).
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mental component summary 26.9 (4.5) vs 43.4 (11.7) in
the bingeing vs non-bingeing heavy drinkers, respectively.
However, the small number of patients limited further
statistical analysis. It is possible that the worse scores in
the binge-drinkers affected the overall outcome of heavy
drinkers.
We speculated about possible mechanisms by which
alcohol consumption attenuates fibromyalgia symptoms,
thus resulting in improved QOL. We showed that low
and moderate alcohol consumption in patients with
fibromyalgia was associated with higher social status, as
noted in other studies in terms of employment [34] and
education [34-36], and favorable BMI in drinkers, as
also noted elsewhere [35,37]. The 1999 to 2006 National
Health and Nutrition Examination Survey in the United
States [36] determined that the percentage of drinkers
increased with higher education level, and current drin-
kers had a lower BMI than never drinkers or former
drinkers. In our study, even after adjusting for social
variables and BMI, we still found the same association
that those with low or moderate alcohol consumption
had fewer fibromyalgia symptoms and higher QOL than
nondrinkers. Thus, socioeconomic status alone appar-
ently does not explain the findings.
Studies suggest that fibromyalgia is a central amplifi-
cation disorder of pain perception due to neurochemical
imbalances in the central nervous system [4,6]. We
believe that a more likely mechanism, in view of our
finding that alcohol consumption attenuates fibromyal-
gia symptoms, might be centrally mediated via g-Amino-
butyric Acid (GABA) system. Previous studies have
demonstrated that ethanol enhances GABA release in
the central nervous system [38,39], and it is interesting
that a recent study showed that GABA levels in the
brain are decreased in patients with fibromyalgia [5].
Gamma-hydroxybutyrate is a metabolite of GABA and
was found to be effective at reducing fibromyalgia symp-
toms but did not receive Food and Drug Administration
Table 3 Comparison of FIQ scores with alcohol use (number of patients = 946)









Total score 65.1 (17.0) 61.0 (15.9) 54.7 (17.1) 62.2 (15.8) <0.001 0.01
Physical function 5.0 (2.2) 4.3 (2.3) 3.6 (2.3) 4.1 (2.4) <0.001 <0.001
Feel good 7.9 (2.2) 7.8 (2.3) 6.7 (2.4) 7.5 (2.5) 0.03 0.10
Work missed 4.7 (3.6) 3.5 (3.5) 2.5 (3.2) 3.7 (3.6) <0.001 0.005
Job ability 7.1 (2.4) 6.5 (2.4) 5.8 (2.1) 6.7 (2.3) <0.001 0.03
Pain 7.3 (2.0) 7.0 (2.1) 5.6 (2.1) 7.1 (1.7) <0.001 0.001
Fatigue 8.3 (2.0) 8.1 (2.0) 7.7 (2.0) 7.9 (2.3) 0.19 0.41
Morning tiredness 7.9 (2.3) 7.8 (2.3) 7.7 (2.1) 8.1 (1.9) 0.71 0.56
Stiffness 7.4 (2.3) 7.3 (2.3) 6.7 (2.4) 7.6 (1.9) 0.39 0.23
Depression 4.3 (3.3) 3.9 (3.1) 3.7 (2.9) 4.4 (3.2) 0.38 0.37
Anxiety 5.1 (3.1) 4.9 (3.0) 4.6 (3.2) 5.2 (2.7) 0.68 0.81
FIQ, Fibromyalgia Impact Questionnaire. aAll values are reported as mean (SD). bAlcohol consumption levels were defined as follows: none, 0 drinks/wk; low, ≤3
drinks/wk; moderate, >3 to 7 drinks/wk; heavy, >7 drinks/wk. cAfter adjusting for age, employment status, education level, body mass index and opioid use.
Table 4 Comparison of SF-36 Scores with alcohol use (number of patients = 946).









Physical functioning 35.5 (21.5) 42.4 (22.4) 51.1 (23.2) 51.5 (22.9) <0.001 <0.001
Role-physical 7.0 (17.5) 9.5 (21.1) 11.3 (24.9) 8.1 (20.8) 0.18 0.32
Pain index 23.0 (14.5) 27.2 (14.9) 32.5 (12.9) 30.4 (15.1) <0.001 0.002
General health perceptions 35.7 (20.0) 41.1 (21.0) 43.5 (18.2) 43.0 (23.6) <0.001 0.02
Vitality 16.3 (15.6) 18.9 (17.0) 19.7 (17.0) 23.7 (15.8) 0.01 0.33
Social functioning 36.4 (25.0) 42.1 (24.3) 47.6 (24.5) 46.0 (25.9) <0.001 0.02
Role-emotional 45.0 (42.9) 48.9 (42.7) 45.2 (41.8) 46.2 (41.9) 0.62 0.91
Mental health index 55.5 (22.1) 58.4 (20.0) 60.8 (20.0) 59.9 (18.9) 0.13 0.51
Physical component summary 25.6 (7.1) 27.9 (7.8) 30.6 (8.1) 30.1 (9.0) <0.001 <0.001
Mental component summary 39.4 (12.0) 40.6 (11.4) 40.4 (11.0) 40.7 (12.4) 0.49 0.76
SF-36, Short Form-36 Health Survey. aAll values are reported as mean (SD). bAlcohol consumption levels were defined as follows: none, 0 drinks/wk; low, ≤3
drinks/wk; moderate, >3 to 7 drinks/wk; heavy, >7 drinks/wk. cAfter adjusting for age, employment status, education level, body mass index and opioid use.
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approval for the management of fibromyalgia because of
concerns about abuse [40,41]. Thus, increase in GABA
production may represent a mechanism by which alco-
hol consumption decreases fibromyalgia symptoms.
It is uncertain whether the effect of alcohol on fibro-
myalgia symptoms and QOL might be mediated by its
psychological benefits as a stress reliever or a factor asso-
ciated with social integration [12,42]. Several studies
showed that small doses of alcohol were associated with
improved mood and decreased depression and tension
[42,43]. Also, its favorable effects on cardiovascular health
might influence QOL, particularly for the elderly [12].
Alcohol can suppress the synthesis of proinflammatory
cytokines and chemokines such as tumor necrosis factor
and interleukin-6, in vivo or in vitro (or both) [44,45], and
it may also have a role as an anti-inflammatory factor.
However, the association of cytokines with fibromyalgia is
controversial [46], with several studies supporting a posi-
tive association [47,48], and another study showing no
association [49]. Alcohol may provide short-term analgesic
effect as demonstrated in a study by James et al. [50], in
which alcohol significantly increased the pain threshold
and decreased the perception of pain after an infusion of
alcohol for 1 hour. In our study, moderate but not heavy
drinkers, had significantly lower FIQ pain than all other
groups, and it is unlikely that the short-term analgesic
effect of alcohol explains the finding.
Alcohol use in our patients was 42%, with most of
them being low-drinkers. The rate of alcohol use among
our patients with fibromyalgia was lower than the 53%
rate for women in the general population [10]. Our study
was based on data from 2001 to 2004. A recent Gallup
report showed that rates of alcohol consumption overall
have stayed stable in spite of some yearly fluctuations
(Gallup report 2012) [51]. Therefore, we believe our find-
ings are still relevant. We observed significant group dif-
ferences in opioid use with the lowest use in the
moderate drinkers and the highest use in the nondrin-
kers, suggesting that the nondrinkers may have more
severe symptoms than the other groups. We cannot rule
out the possibility that the findings were biased by indivi-
duals who did not drink alcohol because of more severe
symptoms of fibromyalgia. The 3% rate of heavy-drinkers
(equivalent to more than one drink per day) in our study
was also lower than the 7% rate for US women [10]. We
do not know why the drinking rate was lower in our
patient group but speculate that it might be related to 1)
decreased social functioning due to chronic pain and
therefore, fewer occasions to drink alcohol socially; 2)
self-perceived chronic health concerns and lower QOL,
leading to different drinking habits; 3) concerns of alco-
hol interacting with medications such as sedatives or nar-
cotics, and 4) possible under-reporting of drinking.
We urge caution when generalizing the findings of this
study because of the relatively small number of moderate
and heavy drinkers in the study. Furthermore, we do not
recommend that patients with fibromyalgia start or increase
drinking for their symptoms. One study showed that alco-
hol abuse was one of the most frequent psychiatric pro-
blems in patients with chronic pain, and a significant
Table 5 Pairwise comparison among alcohol consumption groups



















Tender points 0.76 0.10 0.27 0.04 0.14 0.98
FIQ
Total 0.11 0.049 0.98 0.32 0.61 0.13
Physical function <0.001 0.04 0.76 0.65 0.96 0.60
Work missed 0.004 0.29 0.96 0.97 0.85 0.79
Job ability 0.10 0.11 0.98 0.51 0.97 0.53
Pain 0.61 <0.001 0.98 0.005 0.80 0.009
SF-36
Physical functioning 0.047 0.006 0.01 0.11 0.19 1.00
Pain index 0.02 0.03 0.43 0.39 0.98 0.81
General health perceptions 0.01 0.58 0.84 1.00 0.99 0.99
Social functioning 0.03 0.28 0.86 0.88 0.99 0.88
Physical component summary 0.009 0.01 0.09 0.26 0.69 0.95
FIQ, Fibromyalgia Impact Questionnaire; SF-36, Short Form-36 Health Survey. aAlcohol consumption levels were defined as follows: none, 0 drinks/wk; low, ≤3
drinks/wk; moderate, >3 to 7 drinks/wk; heavy, >7 drinks/wk. bTukey HSD method was used to perform pairwise comparisons of least-squares means between
groups from a multivariate model that adjusted for age, employment status, education level, body mass index and opioid use. P-values <0.05 were considered
statistically significant.
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portion of chronic pain patients had a history of alcohol
abuse before the onset of their pain [52]. Therefore, our
findings should be interpreted carefully.
This study has several limitations. First, the amount of
alcohol consumption in this study was self-reported and
thus may be biased because of possible under-reporting.
However, simple self-administered questionnaires pre-
viously have provided useful estimates of alcohol intake
[53,54]. Our patient population included four patients
who were younger than 21 years (drinking reports: none
(three patients), low (one patient)), which is the legal
drinking age in the US. Our results were the same when
we excluded them. Therefore, we kept them in the
study. Second, we had small sample sizes for those with
moderate and heavy alcohol consumption, and this lim-
ited the power to detect associations in the groups.
Third, the cross-sectional design of the current study
allowed us to say only that low-to-moderate alcohol
consumption appeared to be associated with lower
fibromyalgia symptoms and improved QOL. However,
the reasons for, and the clinical importance of this asso-
ciation cannot be determined in this study, and the
associations may be due to unmeasured confounding
variables. Fourth, we did not use a validated specific
questionnaire for depression, and our study was not
meant to adequately assess depression. Therefore, we
were not able to do further analysis on comorbid psy-
chiatric diagnoses. Fifth, we did not differentiate former
drinkers from abstainers. Previous studies have shown
conflicting findings, ranging from worse QOL in former
drinkers than abstainers [13,14], no difference in subjec-
tive health [55,56], and better QOL in former drinkers
than abstainers [57]. However, this diversity in results
might be due to variations in study design [8]. We also
did not consider the beverage type consumed (for exam-
ple, beer versus wine versus spirits) because the health
effects of alcohol primarily have been attributed to etha-
nol content rather than to other components of each
beverage type [58-60].
Conclusions
Our findings suggest that low-to-moderate alcohol con-
sumption was associated with lower fibromyalgia symp-
toms and better QOL compared to no alcohol
consumption. The mechanism underlying the association
between alcohol consumption and symptom severity in
fibromyalgia requires further investigation. Future studies
may consider assessing the relationship between GABA,
alcohol consumption and fibromyalgia symptoms.
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